Whole genome sequencing for metastatic mutational burden in extraskeletal myxoid chondrosarcoma.

Frontiers in molecular medicine Pub Date : 2023-07-24 eCollection Date: 2023-01-01 DOI:10.3389/fmmed.2023.1152550
Trudy Zou, Rahil Sethi, Jiefei Wang, Gungor Budak, Uma Chandran, Ivy John, Rebecca Watters, Kurt Weiss
{"title":"Whole genome sequencing for metastatic mutational burden in extraskeletal myxoid chondrosarcoma.","authors":"Trudy Zou, Rahil Sethi, Jiefei Wang, Gungor Budak, Uma Chandran, Ivy John, Rebecca Watters, Kurt Weiss","doi":"10.3389/fmmed.2023.1152550","DOIUrl":null,"url":null,"abstract":"<p><p>Extraskeletal myxoid chondrosarcoma (EMC) is an ultra-rare cancer that makes up less than 3% of all soft tissue sarcomas. It most often arises in the soft tissues of the proximal limbs and has a higher incidence in males. Though EMC has a good prognosis, it has an indolent course with high rates of local recurrence as well as metastasis to the lungs. EMC is characterized in 70% of cases by an EWS1-NR4A3 translocation, leading to constitutive expression of NR4A3. Structural variants (SVs) in EMC, especially large-scale genomic alterations, have not been well studied and studies are severely limited by sample size. In this study, we describe Whole Genome Sequencing (WGS) of a rare case of matched EMC primary tumor, lung metastasis, and pelvic metastasis to identify genomic alterations. We examined somatic variants, copy number variants (CNVs), and larger scale SVs such as translocations and breakend points. While the primary tumor and lung metastasis had similar somatic variations and CNVs, the pelvic metastasis had more unique SVs with especially increased mutational burden of SVs in chromosome 2. This suggests that different molecular drivers appear in more advanced, relapsing EMC compared with the primary tumor and early lung metastasis. Genomic studies such as ours may identify novel molecular complexities in rare cancers that may be leveraged for therapeutic strategies and precision medicine.</p>","PeriodicalId":73090,"journal":{"name":"Frontiers in molecular medicine","volume":" ","pages":"1152550"},"PeriodicalIF":0.0000,"publicationDate":"2023-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11285543/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in molecular medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fmmed.2023.1152550","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Extraskeletal myxoid chondrosarcoma (EMC) is an ultra-rare cancer that makes up less than 3% of all soft tissue sarcomas. It most often arises in the soft tissues of the proximal limbs and has a higher incidence in males. Though EMC has a good prognosis, it has an indolent course with high rates of local recurrence as well as metastasis to the lungs. EMC is characterized in 70% of cases by an EWS1-NR4A3 translocation, leading to constitutive expression of NR4A3. Structural variants (SVs) in EMC, especially large-scale genomic alterations, have not been well studied and studies are severely limited by sample size. In this study, we describe Whole Genome Sequencing (WGS) of a rare case of matched EMC primary tumor, lung metastasis, and pelvic metastasis to identify genomic alterations. We examined somatic variants, copy number variants (CNVs), and larger scale SVs such as translocations and breakend points. While the primary tumor and lung metastasis had similar somatic variations and CNVs, the pelvic metastasis had more unique SVs with especially increased mutational burden of SVs in chromosome 2. This suggests that different molecular drivers appear in more advanced, relapsing EMC compared with the primary tumor and early lung metastasis. Genomic studies such as ours may identify novel molecular complexities in rare cancers that may be leveraged for therapeutic strategies and precision medicine.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
骨外黏液软骨肉瘤转移性突变负担的全基因组测序
骨外黏液样软骨肉瘤(EMC)是一种极为罕见的癌症,占所有软组织肉瘤的不到3%。它最常发生在肢体近端软组织,男性发病率较高。虽然EMC预后良好,但病程缓慢,局部复发及肺转移率高。70%的EMC病例以EWS1-NR4A3易位为特征,导致NR4A3的本构性表达。EMC中的结构变异(SVs),特别是大规模的基因组改变,尚未得到很好的研究,而且研究受到样本量的严重限制。在这项研究中,我们描述了一个罕见的匹配EMC原发肿瘤,肺转移和盆腔转移的全基因组测序(WGS),以确定基因组的改变。我们研究了体细胞变异、拷贝数变异(CNVs)和更大规模的sv,如易位和断点。原发肿瘤和肺转移瘤具有相似的体细胞变异和CNVs,而盆腔转移瘤具有更多独特的SVs,特别是2号染色体上SVs的突变负荷增加。这表明,与原发肿瘤和早期肺转移相比,更晚期、复发的EMC出现了不同的分子驱动因素。像我们这样的基因组研究可能会在罕见的癌症中发现新的分子复杂性,这可能会被用于治疗策略和精准医学。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Editorial: Gene therapy and genome editing for metabolic liver disorders. An artificial transcription factor that activates potent interferon-γ expression in human Jurkat T Cells. Immune-checkpoint-inhibitor therapy directed against PD-L1 is tolerated in the heart without manifestation of cardiac inflammation in a preclinical reversible melanoma mouse model. Human-specific gene ARHGAP11B-potentially an additional tool in the treatment of neurodegenerative diseases? DeltaRex-G, tumor targeted retrovector encoding a CCNG1 inhibitor, for CAR-T cell therapy induced cytokine release syndrome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1